Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery

Abstract

A randomized open-heart surgery study comprising 30 patients was undertaken to compare the biocompatibility of Phisio-(phosphorylcholine) and PMEA-(poly-2-methoxyethyl acrylate) coated cardiopulmonary bypass (CPB) circuits and to assess the initial complement pathway activation during open-heart surgery. Blood samples were obtained at five time points, from the start of surgery to 24 hours postoperatively. The following analyses were performed: haemoglobin, lactate dehydrogenase, leukocyte and platelet counts, myeloperoxidase and neutrophil-activating peptide-2, thrombin-anti-thrombin complexes, syndecan-1 and the complement activation products C1rs-C1-inhibitor complexes, C4bc, C3bc, C3bBbP and the terminal complement complex (TCC). No significant inter-group difference was found in any parameters, except for the concentration of TCC which was moderately lower in the PMEA group at termination of CPB. Complement activation during open-heart surgery was mainly mediated through the alternative pathway. In conclusion, PMEA- and Phisio-coated circuits displayed similar biocompatibility with respect to inflammatory and haemostatic responses during and after open-heart surgery.

Keywords

biocompatibility CPB Phisio PMEA complement pathways inflammation

Get full access to this article

View all access options for this article.

References

Zimmermann AK , Weber N. , Aebert H. , Ziemer G. , Wendel HP Effect of biopassive and bioactive surface-coatings on the hemocompatibility of membrane oxygenators . J Biomed Mater Res B-Appl Biomater 2007; 80: 433-439.

Landis RC , Arrowsmith JE , Baker RA , et al. Consensus statement: defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surgery Forum 2008; 11: E316-E322.

Feindt P. , Litmathe J. , Boeken U. , Gams E. Anticoagulation during extracorporeal circulation under conditions of an ongoing systemic inflammatory response syndrome: effects of heparin . Perfusion 2005; 20: 11-15.

Videm V. , Mollnes TE , Garred P. , Svennevig JL Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991; 101: 654-660.

Fosse E. , Thelin S. , Svennevig JL , et al. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study. Eur J Cardiothorac Surg 1997; 11: 320-327.

Thiara AS , Andersen VY , Videm V. , et al. Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response. Perfusion 2010; 25: 9-16.

Baykut D. , Bernet F. , Wehrle J. , Weichett K. , Schwartz P. , Zerkowski HR New surface biopolymers for oxygenators: an in vitro hemocompatibility test of poly (2-methoxyethlacrylate). Eur J Med Res 2001; 6: 297-305.

De Somer F. , van Belleghem Y. , Caes F. , et al. Phosphorycholine coating offers natural platelet preservation during cardiopulmonary bypass. Perfusion 2002 ; 17: 39-44.

Videm V. , Nilsson L. , Venge P. , Svennevig JL Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass. Artif Organs 1991; 15: 90-95.

10.

Fure H. , Nielsen EW , Hack CE , Mollnes TE A neoepitope-based enzyme immunoassay for quantification of C1inhibitor in complex with C1r and C1s. Scand J Immunol 1997; 46: 553-557.

11.

Wolbink GJ , Bollen J. , Baars JW , et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993 ; 163: 67-76.

12.

Garred P. , Mollnes TE , Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27: 329-335.

13.

Mollnes TE , Brekke OL , Fung M. , et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100: 1869-1877.

14.

Mollnes TE , Lea T. , Froland SS , Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22: 197-202.

15.

Mollnes TE , Redl H. , Hogasen K. , et al. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC) . Clin Exp Immunol 1993; 91: 295-300.

16.

Tevaearai HT , Mueller XM , Horisberger J. , et al. In situ control of cardiotomy suction reduces blood trauma. ASAIO J 1998; 44: M380-M383.

17.

Gregoretti S. Suction-induced hemolysis at various vacuum pressures: implications for intraoperative blood salvage. Transfusion 1996; 36: 57-60.

18.

Casati V. , Gerli C. , Franco A. , et al. Activation of coagulation and fibrinolysis during coronary surgery - on-pump versus off-pump techniques. Anesthesiology 2001; 95: 1103-1109.

19.

Sundaram S. , Irvine L. , Courtney JM , Taggart DP , Wheatley DJ , Lowe GDO. Patterns of blood response during cardiopulmonary bypass. Int J Artif Organs 1992; 15: 243-248

20.

Pleym H. , Wahba A. , Videm V. , et al. Increased fibrinolysis and platelet activation in elderly patients undergoing coronary bypass surgery. Anesth Analg 2006; 102: 660-667.

21.

Mulivor AW , Lipowsky HH Inflammation- and ischemia-induced shedding of venular glycocalyx . Am J Physiol Heart Circ Physiol 2004; 286: H1672-H1680.

22.

Harboe M. , Mollnes TE The alternative complement pathway revisited. J Cell Mol Med 2008; 12: 1074-1084.

23.

Bruins P. , te Velthuis H. , Yazdanbakhsh AP , et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 96: 3542-3548.

24.

Nilsson UR , Larm O. , Nilsson B. , Storm KE , Elwing H. , Ekdahl KN Modification of the complement binding properties of polystyrene - effects of endpoint heparin attachment. Scand J Immunol 1993; 37: 349-354.

25.

Harboe M. , Ulvund G. , Vien L. , Fung M. , Mollnes TE The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol 2004; 138: 439-446.

26.

Videm V. , Fosse E. , Mollnes T.E. , Garred P. , Svennevig JL Time for new concepts about measurement of complement activation by cardiopulmonary bypass. Ann Thorac Surg 1992 ; 54: 725-731.